Microbiota‐targeted therapies offer a coherent path to disease modification in ALD and MASLD by restoring barrier function and microbial ecology, reshaping BA/SCFA pools, and dampening endotoxemia with TLR4/NF‐κB/NLRP3 signaling. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.